„”
We congratulate Conor on his successful application for the Walter Benjamin Program with his project “Fragment-based drug discovery of glycan sulfatase inhibitors and chemical probes for investigating gut symbionts in inflammatory bowel disease”.
This project aims to develop the first chemical probes for BT1636 3S-Gal, a glycan sulfatase that enables Bacteroides thetaiotaomicron to degrade mucin and drive gut colonization. Because BT1636 3S-Gal elevated activity is linked to inflammatory bowel disease (IBD), selective inhibition may reduce mucin breakdown and inflammation.
For more information: https://karten-t.dfg.de/gepris/projekt/570219261?language=en
The Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) is part of the Forschungsverbund Berlin e.V. (FVB), which legally represents seven non-university research institutes - members of the Leibniz Association - in Berlin.
Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP)
Rudower Chaussee 17
12489 Berlin, Germany
